Company / EPS (Basic)
Tvardi Therapeutics, Inc. EPS (Basic) History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$19.12
FY2024
5-year range
-$19.12 / $0.18
FY2020-FY2024
Trend
-998.9%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Basic) changed -999% YoY in FY2024, a notable deviation from the 4-year average annual change of -495%.
Based on SEC 10-K filings.
-19.12 in FY2024.
Declined from $0.18 to $-19.12 over the past 2 years.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, eps (basic) decreased 998.9% year-over-year.
- Peak eps (basic) was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$19.12 | -998.9% |
| FY2023 | -$1.74 | -1066.7% |
| FY2022 | $0.18 | +107.2% |
| FY2021 | -$2.49 | -20.9% |
| FY2020 | -$2.06 | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
| FY2015 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026